



## **CDR-Life Announces Pipeline Expansion of Highly Tumor-Targeted T Cell Engagers**

*CDR813 and CDR505 programs further broaden pipeline of cancer-specific targeted therapies*

Zürich, Switzerland, June 25, 2024 – CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505.

CDR813 is a highly potent and selective TCE candidate targeting tumors expressing PRAME (preferentially expressed antigen in melanoma) in HLA-A\*02:01 patients. PRAME is a clinically validated pan-cancer target expressed in a broad set of tumors including non-small cell lung cancer (NSCLC), endometrial cancer, melanoma and ovarian cancer, but not in normal tissue. A bi-valent and bi-specific antibody-based TCE, CDR813 targets a PRAME peptide presented on tumor cells by the HLA-A\*02 complex and the CD3 receptor on T-cells with unparalleled potency and specificity.

CDR505 is a TCE targeting KK-LC-1, a novel HLA-A\*01 target relevant in common cancer populations not yet addressed by other T cell receptors (TCR) therapeutics. While most TCE programs target the HLA-A02 haplotype, CDR505 targets KK-LC-1/HLA-A\*01, expanding the potential of TCEs to benefit a large patient population with high unmet need. [Preclinical data on CDR505](#) was presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2024.

“With our continued investment in building a broad pipeline of unique, potent and highly cancer-targeted therapies, we are expanding the promise of our differentiated T cell engager platform to treat a range of solid tumors,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “Importantly, the CDR813 and CDR505 programs are geared toward populations with significant unmet medical need, increasing our reach to benefit more patients.”

### **About CDR-Life**

CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.

### **Contacts**

Media:

Lauren Arnold

LA Communications

Lauren@lacommunications.net